Aldehyde dehydrogenase genes as prospective actionable targets in acute myeloid leukemia

Basit Öğe Kaydı
dc.authorid0000-0002-4337-9327en_US
dc.authorid0000-0003-0172-6957en_US
dc.contributor.authorDancik, Garrett M.
dc.contributor.authorVarışli, Lokman
dc.contributor.authorTolan, Veysel
dc.contributor.authorVlahopoulos, Spiros
dc.date.accessioned2023-10-03T12:31:49Z
dc.date.available2023-10-03T12:31:49Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.description.abstractIt has been previously shown that the aldehyde dehydrogenase (ALDH) family member ALDH1A1 has a significant association with acute myeloid leukemia (AML) patient risk group classification and that AML cells lacking ALDH1A1 expression can be readily killed via chemotherapy. In the past, however, a redundancy between the activities of subgroup members of the ALDH family has hampered the search for conclusive evidence to address the role of specific ALDH genes. Here, we describe the bioinformatics evaluation of all nineteen member genes of the ALDH family as prospective actionable targets for the development of methods aimed to improve AML treatment. We implicate ALDH1A1 in the development of recurrent AML, and we show that from the nineteen members of the ALDH family, ALDH1A1 and ALDH2 have the strongest association with AML patient risk group classification. Furthermore, we discover that the sum of the expression values for RNA from the genes, ALDH1A1 and ALDH2, has a stronger association with AML patient risk group classification and survival than either one gene alone does. In conclusion, we identify ALDH1A1 and ALDH2 as prospective actionable targets for the treatment of AML in high-risk patients. Substances that inhibit both enzymatic activities constitute potentially effective pharmaceutics.en_US
dc.identifier.citationDancik, G.M., Varışli, L., Tolan, V. ve Vlahopoulos, S. (2023). Aldehyde dehydrogenase genes as prospective actionable targets in acute myeloid leukemia. Genes, 14(9), 1807.en_US
dc.identifier.doi10.3390/genes14091807
dc.identifier.endpage15en_US
dc.identifier.issn2073-4425
dc.identifier.issue9en_US
dc.identifier.pmid37761947
dc.identifier.scopus2-s2.0-85172812823
dc.identifier.scopusqualityQ2
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.mdpi.com/2073-4425/14/9/1807
dc.identifier.urihttps://hdl.handle.net/11468/12708
dc.identifier.volume14en_US
dc.identifier.wosWOS:001075705500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorVarışli, Lokman
dc.institutionauthorTolan, Veysel
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofGenes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancer bioinformaticsen_US
dc.subjectAldehyde dehydrogenaseen_US
dc.subjectBiomarkersen_US
dc.subjectGene expressionen_US
dc.subjectLeukemiaen_US
dc.subjectMyeloiden_US
dc.subjectAcuteen_US
dc.titleAldehyde dehydrogenase genes as prospective actionable targets in acute myeloid leukemiaen_US
dc.titleAldehyde dehydrogenase genes as prospective actionable targets in acute myeloid leukemia
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
genes-14-01807.pdf
Boyut:
2.78 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Moleküler Biyoloji ve Genetik Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu